← Back to Search

Neurotoxin

Low-Dose Botox for Urinary Incontinence (RELIEF Trial)

Phase 1 & 2
Recruiting
Led By Anne C Cooper, MD
Research Sponsored by Dartmouth-Hitchcock Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adult female at least 70 years old at date of enrollment
On average 2 or more urgency or insensible incontinence episodes per day per patient report
Must not have
Greater than stage 2 pelvic floor prolapse, uncorrected or persistent despite pessary use
Lack of capacity to provide consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3, 6, & 12 months post injection. results will be compared at the end of the 12 months.
Awards & highlights
No Placebo-Only Group

Summary

This trial will study a lower dose of Botox to treat urinary incontinence in women over 70.

Who is the study for?
This trial is for women aged 70 or older with urgency urinary incontinence who've tried other treatments without success. They should be able to handle catheterization if needed, have no major neurological issues affecting bladder function, and not be using certain medications or therapies that could interfere with the study.
What is being tested?
The study compares two doses of Botox injections (50 units vs. 100 units) in treating urinary urgency among elderly females. It aims to determine whether a reduced dose can effectively manage symptoms while potentially minimizing side effects.
What are the potential side effects?
Possible side effects include difficulty emptying the bladder requiring temporary catheterization, urinary tract infections, discomfort at the injection site, and allergic reactions to components like lidocaine or Botox itself.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a woman aged 70 or older.
Select...
I experience 2 or more sudden urges to urinate or involuntary urine leaks daily.
Select...
I am not using sacral neuromodulation therapy.
Select...
My severe urge to urinate hasn't improved despite trying medications or other treatments.
Select...
My nervous system functions normally and does not affect my bladder control.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My pelvic floor prolapse is severe and hasn't improved with a pessary.
Select...
I am unable to understand and give consent for treatment.
Select...
I need my Botox injections to be done in an Operating Room or while I'm sedated.
Select...
I have used more than 300 units of Botox for another condition in the last 3 months.
Select...
I currently have a urinary tract infection that hasn't been treated.
Select...
I have a history of bladder issues, including cancer or severe inflammation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3, 6, & 12 months post injection. results will be compared at the end of the 12 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3, 6, & 12 months post injection. results will be compared at the end of the 12 months. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in symptom specific quality of life and bother over time.
Secondary study objectives
Change in Global Symptom Improvement
Change in general health-related quality of life as measure by the Health Utility Index-3
Change in number of urgency urinary incontinence (UUI) episodes per day.
+7 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Botox: Low doseExperimental Treatment1 Intervention
A lower dose of 50 units of botox will be injected into the bladder.
Group II: Botox: Standard doseActive Control1 Intervention
The standard dose of 100 units of botox will be injected into the bladder.

Find a Location

Who is running the clinical trial?

Dartmouth CollegeOTHER
86 Previous Clinical Trials
1,419,362 Total Patients Enrolled
University of Alabama at BirminghamOTHER
1,656 Previous Clinical Trials
2,443,999 Total Patients Enrolled
15 Trials studying Urinary Incontinence
6,787 Patients Enrolled for Urinary Incontinence
University of PittsburghOTHER
1,792 Previous Clinical Trials
16,359,610 Total Patients Enrolled
11 Trials studying Urinary Incontinence
3,026 Patients Enrolled for Urinary Incontinence
University of TexasOTHER
189 Previous Clinical Trials
142,592 Total Patients Enrolled
2 Trials studying Urinary Incontinence
682 Patients Enrolled for Urinary Incontinence
Kaiser PermanenteOTHER
556 Previous Clinical Trials
27,731,859 Total Patients Enrolled
10 Trials studying Urinary Incontinence
4,065 Patients Enrolled for Urinary Incontinence
Oregon Health and Science UniversityOTHER
1,008 Previous Clinical Trials
7,413,933 Total Patients Enrolled
5 Trials studying Urinary Incontinence
650 Patients Enrolled for Urinary Incontinence
Stanford UniversityOTHER
2,491 Previous Clinical Trials
17,517,788 Total Patients Enrolled
4 Trials studying Urinary Incontinence
290 Patients Enrolled for Urinary Incontinence
University of ConnecticutOTHER
192 Previous Clinical Trials
160,504 Total Patients Enrolled
Dartmouth-Hitchcock Medical CenterLead Sponsor
539 Previous Clinical Trials
2,539,389 Total Patients Enrolled
Patient-Centered Outcomes Research InstituteOTHER
580 Previous Clinical Trials
27,104,883 Total Patients Enrolled
2 Trials studying Urinary Incontinence
1,632 Patients Enrolled for Urinary Incontinence

Media Library

Botox (Neurotoxin) Clinical Trial Eligibility Overview. Trial Name: NCT05512039 — Phase 1 & 2
Urinary Incontinence Research Study Groups: Botox: Standard dose, Botox: Low dose
Urinary Incontinence Clinical Trial 2023: Botox Highlights & Side Effects. Trial Name: NCT05512039 — Phase 1 & 2
Botox (Neurotoxin) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05512039 — Phase 1 & 2
~193 spots leftby Sep 2026